<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00620620</url>
  </required_header>
  <id_info>
    <org_study_id>AMDC-007-101</org_study_id>
    <secondary_id>17 December 2007</secondary_id>
    <nct_id>NCT00620620</nct_id>
  </id_info>
  <brief_title>Staccato Zaleplon Single Dose Pharmacokinetics</brief_title>
  <official_title>Safety, Tolerability, and Pharmacokinetics of a Single Dose of StaccatoÂ® Zaleplon for Inhalation in Healthy Volunteers</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Alexza Pharmaceuticals, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Alexza Pharmaceuticals, Inc.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of the study is to determine the safety, tolerability and pharmacokinetics of
      zaleplon delivered by the Staccato thermal aerosol system in healthy volunteers
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>February 2008</start_date>
  <completion_date type="Actual">March 2008</completion_date>
  <primary_completion_date type="Actual">March 2008</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Examine the tolerability and safety of Staccato Zaleplon in a healthy volunteer population;</measure>
    <time_frame>Single dose</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Establish the plasma level-time profile (pharmacokinetics) of zaleplon in the target therapeutic range following single Staccato Zaleplon doses</measure>
    <time_frame>single dose</time_frame>
  </secondary_outcome>
  <number_of_arms>5</number_of_arms>
  <enrollment type="Actual">40</enrollment>
  <condition>Healthy</condition>
  <arm_group>
    <arm_group_label>Inhaled Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Staccato Placebo</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Inhaled Zaleplon 0.5 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Staccato Zaleplon 0.5 mg</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Inhaled Zaleplon 1 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Staccato Zaleplon 1 mg</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Inhaled Zaleplon 2 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Staccato Zaleplon 2 mg</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Inhaled Zaleplon 4 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Staccato Zaleplon 4 mg</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Inhaled placebo</intervention_name>
    <description>Inhaled Staccato Placebo</description>
    <arm_group_label>Inhaled Placebo</arm_group_label>
    <other_name>Staccato Placebo</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Inhaled Zaleplon 0.5 mg</intervention_name>
    <description>Inhaled Staccato Zaleplon 0.5 mg</description>
    <arm_group_label>Inhaled Zaleplon 0.5 mg</arm_group_label>
    <other_name>Staccato Zaleplon 0.5 mg</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Inhaled Zaleplon 1 mg</intervention_name>
    <description>Inhaled Staccato Zaleplon 1 mg</description>
    <arm_group_label>Inhaled Zaleplon 1 mg</arm_group_label>
    <other_name>Staccato Zaleplon 1 mg</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Inhaled Zaleplon 2 mg</intervention_name>
    <description>Inhaled Staccato Zaleplon 2 mg</description>
    <arm_group_label>Inhaled Zaleplon 2 mg</arm_group_label>
    <other_name>Staccato Zaleplon 2 mg</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Inhaled Zaleplon 4 mg</intervention_name>
    <description>Inhaled Staccato Zaleplon 4 mg</description>
    <arm_group_label>Inhaled Zaleplon 4 mg</arm_group_label>
    <other_name>Staccato Zaleplon 4 mg</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Male and female subjects between the ages of 18 to 55 years, inclusive who are in good
             general health

        Exclusion Criteria:

          -  Subjects with a history of allergy or intolerance to zaleplon. Subjects who have any
             other disease or condition, by history, physical examination, or laboratory
             abnormalities that in the investigator's opinion, would present undue risk to the
             subject, or may confound the interpretation of study results.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>55 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Daniel A Spyker, MD</last_name>
    <role>Study Director</role>
    <affiliation>Alexza Pharmaceuticals, Inc.</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Covance Clinical Research Unit Inc.</name>
      <address>
        <city>Evansville</city>
        <state>Indiana</state>
        <zip>47714</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <reference>
    <citation>Avram MJ, Spyker DA, Kehne JH, Cassella JV. The pharmacokinetics and pharmacodynamics of zaleplon delivered as a thermally generated aerosol in a single breath to volunteers. J Clin Pharmacol. 2013 Feb;53(2):140-50. doi: 10.1177/0091270012436886.</citation>
    <PMID>23436259</PMID>
  </reference>
  <verification_date>July 2013</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>February 7, 2008</study_first_submitted>
  <study_first_submitted_qc>February 19, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 21, 2008</study_first_posted>
  <last_update_submitted>March 13, 2017</last_update_submitted>
  <last_update_submitted_qc>March 13, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">March 14, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Healthy adult volunteers</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Zaleplon</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>IPD submitted to regulatory authorities. Others may contact Alexza Pharmaceuticals, Inc. Please send your request to ClinicalTrialsInfo@alexza.com</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

